Abstract
This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among 66 007 patients with coronavirus disease 2019 in a large health care system. A possible contradiction was present in 9830 patients (14.8%), with the prevalence of contraindications increasing with higher acuity of illness.
Original language | English (US) |
---|---|
Article number | ofac389 |
Journal | Open Forum Infectious Diseases |
Volume | 9 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2022 |
Bibliographical note
Publisher Copyright:© 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Keywords
- COVID-19
- Palovid
- contraindications
- nirmatrelvir/ritonavir
PubMed: MeSH publication types
- Journal Article